Senin, 25 Mei 2015

Tugas Softskill



Sejarah, Visi,  Misi dan Perkembangan PT Bayer
Bayer AG  adalah sebuah perusahaan kimia dan farmasi Jerman yang didirikan pada tahun 1863 oleh Friedrich Bayer yang bermarkas di Leverkusen, North Rhine-Westphalia, Jerman. Perusahaan ini terkenal dengan aspirinnya, produk lain yang di produksi oleh PT Bayer adalah obat hewan, obat generik dan khusus, produk kesehatan wanita, obat bebas, produk penderita diabetes, pestisida, bioteknologi tanaman, polimer, lem dll
Anak perusahaan PT Bayer diantaranya adalah Bayer MaterialScience, Bayer USA, Bayer Schering Pharma, Bayer HealthCare Pharmaceuticals, Bayer CropScience. DiIndonesia, lisensi produk-produk buatan Bayer dipegang oleh PT Bayer Indonesia. PT.Bayer Indonesia merupakan perusahaan swasta yang bergerak di bidang obat-obatan, didirikan pada tanggal 14 Maret 1969 dengan akte notaris atas nama Elisa Pondang nomor 20 yang disahkan oleh Menteri Kehakiman No. 7A5. 32. 25 tertanggal 25 Maret 1969.
Pada tahun 1969, PT Bayer Indonesia hanya berfungsi sebagai distributor produksi obat-obatan perusahaan Bayer negara lainya.  Pada tahun 1971 PT Bayer Indonesia mulai memproduksi obat-obatan yang digunakan untuk manusia dengan nama PT Bayer Pharma Indonesia yang berlokasi di Jalan Raya Bogor Km 28, Cibubur. Pada tanggal 1972, PT Bayer Pharma Indonesia mengembangkan usahanya dengan mendirikan PT Bayer Agro Chemical yang memproduksi obat-obatan serangga seperti insektisida, pestisida, dan lain-lain. PT Bayer Agro Chemical ini berlokasi di Kawasan Industri Pulo Gadung.
Pada tahun 1981, PT Bayer Pharma Indonesia dan PT Bayer Agro Chemical semakin berkembang dan mendirikan  PT Bayer Anyer Chemical di Gresik, Jawa Timur (sekarang sudah ditutup). PT Bayer Anyer Chemical ini memproduksi bahan-bahan makanan ternak, obat-obatan untuk ternak, dan bahan baku obat yang diperlukan PT Bayer Pharma Indonesia (misalnya asetosal dan piperazin).
Pada bulan Mei 1982, dilakukan penggabungan (merger) antara PT Bayer Pharma Indonesia, PT Bayer Agro Chemical, dan PT Bayer Anyer Chemical sehingga berubah menjadi PT Bayer Indonesia yang berlokasi di Cibubur, Jakarta Timur sampai sekarang.
Tahun 1982, perseroan melakukan “go public” dan menawarkan sahamnya di Bursa Efek Jakarta (BEJ). Tahun 1997, PT Bayer Indonesia berubah nama menjadi PT Bayer Indonesia Tbk. Pada tahun 1998 PT Bayer Indonesia Tbk. mendapat sertifikat ISO 9002.
Tanggal 31 Desember 2002, PT Bayer Indonesia Tbk. melakukan divestasi usaha produk kesehatan rumah tangga setelah pemegang saham PT Bayer Indonesia Tbk. menyetujui penjualan produk kesehatan rumah tangga kepada PT Johnson Home Hygiene Products pada Rapat Umum Pemegang Saham Luar Biasa (RUPSLB).
Pada saat yang sama perseroan membeli seluruh saham PT Aventis Crop Science Indonesia. Penggabungan usaha agro kimia dua perusahaan tersebut telah menempatan perseroan di jajaran atas pemimpin pasar.
Pada tanggal 3 Januari 2005, PT Bayer Indonesia membeli PT Roche divisi OTC. Sekarang PT Bayer Indonesia mempunyai dua buah pabrik yang memproduksi obat-obatan. Pabrik tersebut berlokasi di Cibubur dan Cimanggis yang sampai kini dikenal dengan pabrik Bayer Cibubur dan pabrik Bayer Cimanggis.
Komitmen PT Bayer Indonesia sebagai salah satu perusahaan yang melaksanakan pembangunan berkelanjutan (sustainable development) kembali ditunjukkan dengan menyelenggarakan salah satu program bagi generasi muda untuk memberikan kontribusi terutama dalam bidang pelestarian lingkungan yaitu Bayer Young Enviromental Envoy (BYEE).
Program BYEE merupakan hasil kerjasama antara Bayer dengan United Nations Environment Programme (UNEP) untuk mendukung generasi muda dalam berkomitmen terhadap aktifitas perlindungan lingkungan.

Visi : Terdapat di dalam slogan Bayer: Ilmu Untuk Sebuah Kehidupan Yang Lebih Baik

Misi :  1. Untuk menjadi perusahaan global yang inovatif di bidang farmasi dan medis, serta bidang pertanian, serta bidang material.
2.Untuk menjadi perusahaan yang mempunyai sumber daya manusia yang mempunyai kompetensi dan motivasi yang tinggi sehingga mampu diandalkan, mempunyai teknologi yang unggul sedunia sehingga menunjang di dalam rangka mengembangkan inovasi, mempunyai produk yang bermutu tinggi, serta mempunyai penyediaan pelayanan yang sempurna bagi kehidupan khususnya kehidupan manusia

Laporan Keuangan :
Note
2013
2014


€ million
€ million
Net sales
40,157
42,239
Cost of goods sold

(19,516)
(20,266)
Gross profit

20,641
21,973




Selling expenses
(10,312)
(11,018)
Research and development expenses
(3,406)
(3,574)
General administration expenses

(1,712)
(1,741)
Other operating income
887
716
Other operating expenses
(1,164)
(850)
EBIT1

4,934
5,506




Equity-method loss
(16)
(13)
Financial income

389
343
Financial expenses

(1,100)
(1,311)
Financial result
(727)
(981)




Income before income taxes

4,207
4,525




Income taxes
(1,021)
(1,082)




Income after income taxes

3,186
3,443
of which attributable to non-controlling interest
(3)
17
of which attributable to Bayer AG stockholders (net income)

3,189
3,426






Earnings per share


Basic

3.86
4.14
Diluted

3.86
4.14
2013 figures restated
1 EBIT: earnings before financial result and taxes

   [Table 4.2]

Note
2013
2014


€ million
€ million
Income after income taxes

3,186
3,443
of which attributable to non-controlling interest
(3)
17
of which attributable to Bayer AG stockholders

3,189
3,426




Remeasurements of the net defined benefit liability for post-employment benefit plans
1,946
(5,159)
Income taxes
(604)
1,621
Other comprehensive income from remeasurements of the net defined benefit liability for post-employment benefit plans

1,342
(3,538)




Other comprehensive income that will not be reclassified subsequently to profit or loss

1,342
(3,538)




Changes in fair values of derivatives designated as cash flow hedges
221
(146)
Reclassified to profit or loss

(156)
(46)
Income taxes
(18)
57
Other comprehensive income from cash flow hedges

47
(135)




Changes in fair values of available-for-sale financial assets
52
Reclassified to profit or loss

(76)
Income taxes
16
(2)
Other comprehensive income from available-for-sale financial assets

(8)
(2)




Changes in exchange differences recognized on translation of operations outside the eurozone

(737)
1,384
Reclassified to profit or loss

Other comprehensive income from exchange differences

(737)
1,384




Other comprehensive income that may be reclassified subsequently to profit or loss

(698)
1,247




Effects of changes in scope of consolidation

(1)




Total other comprehensive income1

643
(2,291)
of which attributable to non-controlling interest

(14)
11
of which attributable to Bayer AG stockholders

657
(2,302)




Total comprehensive income

3,829
1,152
of which attributable to non-controlling interest

(17)
28
of which attributable to Bayer AG stockholders

3,846
1,124
1 total changes recognized outside profit or loss



Note
Dec. 31, 2013
Dec. 31, 2014


€ million
€ million
Noncurrent assets



Goodwill
9,862
16,168
Other intangible assets
8,914
15,653
Property, plant and equipment
10,015
11,428
Investments accounted for using the equity method
203
223
Other financial assets
1,203
1,107
Other receivables
496
447
Deferred taxes
1,596
2,981


32,289
48,007
Current assets



Inventories
7,129
8,478
Trade accounts receivable
7,569
9,097
Other financial assets
779
723
Other receivables
1,476
1,488
Claims for income tax refunds

413
588
Cash and cash equivalents

1,662
1,853


19,028
22,227




Total assets

51,317
70,234




Equity


Capital stock of Bayer AG

2,117
2,117
Capital reserves of Bayer AG

6,167
6,167
Other reserves

12,434
11,822
Equity attributable to Bayer AG stockholders

20,718
20,106
Equity attributable to non-controlling interest

86
112


20,804
20,218




Noncurrent liabilities



Provisions for pensions and other post-employment benefits
7,368
12,236
Other provisions
1,977
2,016
Financial liabilities
5,590
18,484
Other liabilities
362
1,088
Deferred taxes
1,193
689


16,490
34,513
Current liabilities



Other provisions
4,727
4,912
Financial liabilities
3,441
3,376
Trade accounts payable
4,473
5,363
Income tax liabilities
101
63
Other liabilities
1,281
1,789


14,023
15,503




Total equity and liabilities

51,317
70

Note
2013
2014


€ million
€ million
Income after income taxes

3,186
3,443
Income taxes

1,021
1,082
Financial result

727
981
Income taxes paid or accrued

(1,644)
(1,315)
Depreciation, amortization and impairments

2,896
2,936
Change in pension provisions

(249)
(337)
(Gains) losses on retirements of noncurrent assets

(105)
30
Gross cash flow

5,832
6,820




Decrease (increase) in inventories

(608)
(741)
Decrease (increase) in trade accounts receivable

(751)
(1,094)
(Decrease) increase in trade accounts payable

389
518
Changes in other working capital, other non-cash items

309
307
Net cash provided by (used in) operating activities (net cash flow)
5,171
5,810




Cash outflows for additions to property, plant, equipment and intangible assets

(2,157)
(2,371)
Cash inflows from sales of property, plant, equipment and other assets

153
143
Cash inflows from divestitures

79
304
Cash inflows from (outflows for) noncurrent financial assets

204
(10)
Cash outflows for acquisitions less acquired cash

(1,082)
(13,545)
Interest and dividends received

125
107
Cash inflows from (outflows for) current financial assets

97
(167)
Net cash provided by (used in) investing activities
(2,581)
(15,539)




Dividend payments

(1,574)
(1,739)
Issuances of debt

9,078
27,584
Retirements of debt

(9,697)
(15,746)
Interest paid including interest-rate swaps

(550)
(541)
Interest received from interest-rate swaps

212
179
Cash outflows for the purchase of additional interests in subsidiaries

(4)
(1)
Net cash provided by (used in) financing activities
(2,535)
9,736




Change in cash and cash equivalents due to business activities

55
7




Cash and cash equivalents at beginning of year

1,698
1,662




Change in cash and cash equivalents due to changes in scope of consolidation

Change in cash and cash equivalents due to exchange rate movements

(91)
184




Cash and cash equivalents at end of year

1,662
1,853

Five-Year Summary


2010
2011
2012
2013
2014

€ million
€ million
€ million
€ million
€ million
Bayer Group





Sales
35,088
36,528
39,741
40,157
42,239
Sales outside Germany
87.4%
87.3%
88.3%
87.9%
88.2%
EBIT1
2,730
4,149
3,928
4,934
5,506
EBIT before special items2
4,452
5,025
5,639
5,773
5,944
EBITDA2
6,286
6,918
6,916
7,830
8,442
EBITDA before special items2
7,101
7,613
8,280
8,401
8,812
Income before income taxes
1,721
3,363
3,176
4,207
4,525
Income after income taxes
1,310
2,472
2,453
3,186
3,443
Earnings per share (€)3
1.57
2.99
2.91
3.86
4.14
Core earnings per share (€)
4.19
4.83
5.30
5.61
6.02
Noncurrent assets
33,188
32,697
32,308
32,289
48,007
of which goodwill and other intangible assets
20,163
19,455
18,757
18,776
31,821
of which property, plant and equipment
9,835
9,823
9,898
10,015
11,428
Current assets
18,318
20,068
19,010
19,028
22,227
Inventories
6,104
6,368
6,991
7,129
8,478
Receivables and other current assets
9,374
11,846
10,321
10,237
11,896
Cash and cash equivalents
2,840
1,770
1,698
1,662
1,853
Financial liabilities
11,833
11,679
9,530
9,031
21,860
Noncurrent
9,944
7,995
6,962
5,590
18,484
Current
1,889
3,684
2,568
3,441
3,376
Interest expense – net
(499)
(335)
(252)
(355)
(356)
Return on equity
6.9%
13.0%
13.0%
16.2%
16.8%
Gross cash flow4
4,771
5,172
4,556
5,832
6,820
Capital expenditures (total)
1,621
1,666
1,929
2,157
2,371
Depreciation and amortization
2,571
2,521
2,641
2,611
2,713
Research and development expenses
3,053
2,932
3,013
3,406
3,574
Equity including non-controlling interest (total)
18,896
19,271
18,551
20,804
20,218
Capital stock
2,117
2,117
2,117
2,117
2,117
Reserves
16,779
17,154
16,434
18,687
18,101
Net income
1,301
2,470
2,403
3,189
3,426
Non-controlling interest
63
59
100
86
112
Liabilities (total)
32,610
33,494
32,767
30,513
50,016
Total assets
51,506
52,765
51,318
51,317
70,234
Equity ratio
36.7%
36.5%
36.1%
40.5%
28.8%
Bayer AG





Net income
1,245
1,125
889
2,498
2,454
Allocation to (withdrawal from) retained earnings
5
(239)
(682)
761
593
Total dividend payment
1,240
1,364
1,571
1,737
1,861
Dividend per share (€)
1.50
1.65
1.90
2.10
2.25
Employees





Number of employees5(Dec. 31)
111,400
111,800
110,000
112,400
118,900
Personnel expenses (including pension expenses) (€ million)
8,099
8,726
9,194
9,430
9,845
Proportion of women in senior management (%)
21
22
23
25
26
Number of nationalities in the Group Leadership Circle
21
22
23
31
35
Proportion of employees with health insurance (%)
94
94
94
95
96
Proportion of employees covered by collective agreements on pay and conditions (%)
55
54
53
54
52
Safety





Recordable Incident Rate for Bayer employees (RIR)
0.62
0.56
0.49
0.47
0.43
Lost Time Recordable Incident Rate for Bayer employees (LTRIR)
0.34
0.31
0.27
0.26
0.22
Loss of Primary Containment Incident Rate (LoPC-IR)6
0.38
0.35
0.23
Number of transport incidents
8
7
6
11
12
Environmental Protection





Direct greenhouse gas emissions
(CO2 equivalents in million t)7
4.80
4.23
4.24
4.09
4.02
Indirect greenhouse gas emissions
(CO2 equivalents in million t)7
3.70
3.92
4.12
4.29
4.70
Volatile organic compounds
(VOC) (thousand t/a)8
2.54
2.69
2.60
2.27
2.12
Ozone-depleting substances
(ODS) (t/a)9
20.77
16.31
16.28
15.65
14.79
Total organic carbon (TOC)
(thousand t/a)
1.42
1.50
1.42
1.53
1.20
Total phosphorus in wastewater
(thousand t/a)
0.09
0.08
0.15
0.11
0.10
Total nitrogen in wastewater
(thousand t/a)
0.49
0.53
0.70
0.69
0.76
Hazardous waste generated
(thousand t/a)
354
474
603
467
487
Hazardous waste landfilled
(thousand t/a)
56
122
175
53
65
Water use
(million m³/a)
474
411
384
361
350
Primary energy consumption
(petajoules/a)10
51.63
50.10
49.05
47.58
45.57
Secondary energy consumption
(petajoules/a)10
34.08
34.85
34.14
33.27
39.74
Energy efficiency (MWh/t)11
3.77
3.63
3.50
3.44
3.37
2013 figures restated; figures for 2010-2012 as last reported 
1 EBIT = earnings before financial result and taxes
2 For definition see Combined Management Report, Chapter 16.2 “Calculation of EBIT(DA) Before Special Items.”
3 Earnings per share as defined in IAS 33 = net income divided by the average number of shares. For details see Note [16] to the consolidated financial statements. 
4 For definition see Combined Management Report, Chapter 16.5 “Liquidity and Capital Expenditures of the Bayer Group.”
5 Full-time equivalents
6 LoPC-IR: rate of incidents in which chemicals leak from their primary container, such as pipelines, pumps, tanks or drums, per 200,000 working hours in areas relevant to plant safety. LoPC-IR has been recorded since 2012.
7 Portfolio-adjusted in accordance with the Greenhouse Gas Protocol
8 Volatile organic compounds (VOC) excluding methane
9 Ozone-depleting substances (ODS) in CFC-11 equivalents
10 1 petajoule = 1015 joules
11 Energy efficiency: quotient of total energy consumption and manufactured sales volume. For MaterialScience, only manufactured sales volumes that also form the basis for calculating MaterialScience-specific emissions are taken into account.


Sumber :